With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented, especially in the segment of immunoglobulins. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobulins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. IgG is naturally manufactured by plasma cells in human body. IgG antibody, also known as immunoglobulin-G is a large Y-shaped protein employed by the body’s immune system for neutralizing foreign substances like viruses and bacteria. Intravenous immunoglobulin (IVIG) is a blood plasma derivative administered intravenously. It comprises of pooled, polyvalent, IgG (immunoglobulin (antibody) G) extracted from the plasma of more than one thousand blood donors. The very blood plasma derivative is deployed mainly in the treatment of autoimmune disorders, immune deficiencies and acute infections. IVIG has been the key factor to drive the growth of plasma products industry. The demand for IVIG has been growing on account of its increased usage in the treatment of primary immunodeficiency as well as newer neurological indications. The present report offers an analysis of the global IVIG market with a special focus on the IVIG market of the US. The market is characterized by fast pace developments in the clinical technology and testing methodology. Despite challenges like stringent regulations and high cost of treatment, the global IVIG market is all set to witness high growth in the coming years as a result of growing ageing population, increasing number of patients with bleeding disorder, and rising health expenditure. Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global IVIG plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, and Grifols.

1. Global IVIG Market
------------------------------
2013
View Report Details

2. Executive Summary
With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic
industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to
changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented, especially in the segment of
immunoglobulins. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function
impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors
etc. which are derived from human blood plasma.
Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with
the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobulins. Plasma is the raw material for the
extraction of various proteins which are used for their therapeutic values. IgG is naturally manufactured by plasma cells in human body. IgG
antibody, also known as immunoglobulin-G is a large Y-shaped protein employed by the body’s immune system for neutralizing foreign
substances like viruses and bacteria.
Intravenous immunoglobulin (IVIG) is a blood plasma derivative administered intravenously. It comprises of pooled, polyvalent, IgG
(immunoglobulin (antibody) G) extracted from the plasma of more than one thousand blood donors. The very blood plasma derivative is
deployed mainly in the treatment of autoimmune disorders, immune deficiencies and acute infections. IVIG has been the key factor to drive
the growth of plasma products industry. The demand for IVIG has been growing on account of its increased usage in the treatment of primary
immunodeficiency as well as newer neurological indications.
The present report offers an analysis of the global IVIG market with a special focus on the IVIG market of the US. The market is characterized
by fast pace developments in the clinical technology and testing methodology. Despite challenges like stringent regulations and high cost of
treatment, the global IVIG market is all set to witness high growth in the coming years as a result of growing ageing population, increasing
number of patients with bleeding disorder, and rising health expenditure. Furthermore, the competitive landscape of the industry is
highlighted. The rivalry prevalent in the global IVIG plasma market is quite fierce with numerous local and global players contenting for the
market share. On the global front, the key players are Baxter, CSL, and Grifols.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the
industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to
determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or
predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables, and tests.
View Report Details

3. Plasma is the raw material for the extraction of various proteins. It can be divided into two categories
depending on how it is obtained viz. Source plasma and Recovered plasma...
The global blood plasma market was valued at US$.......billion in
2010, and reached US$....... billion in 2011, depicting an increase
of ……….% approximately. The recorded CAGR over the cited
period was …….%.
In terms of products, in 2011, the global blood plasma market
was dominated by IVIGs or IGs with a significant share of ……..%
followed by FVIII with …….% share. FIX and albumin constituted
……% share each.
 As of 2011, the global sales of immunoglobulins stood at
US$...... billion, registering a modest growth of …….% over the
value of 2010. For the period of 7 years spanning from 2004 to
2011, the global IVIG market recorded an impressive CAGR of
…………%.
IG Factor VIII Factor IX Albumin Other Products
Global Blood Plasma Market (2000-2011)
Global Plasma Market Share by Product (2011)
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
US$ Billion
Global IVIG Market Size (2004-2011)
2004 2005 2006 2007 2008 2009 2010 2011
US$Billion

4. IgG is naturally manufactured by plasma cells in human body. IgG antibody, also known as an
immunoglobulin-G is a large Y-shaped protein employed by the body’s immune system for neutralizing
foreign substances like viruses and bacteria.
Over the years, the demand and supply of IVIG have been in sync
with each other. Although, in some years the supply exceeded the
demand; like in 2009 and 2010, the demand was of ………..and
…….. tonnes approximately, whereas the supply of the same stood at
……… and …….. tonnes, respectively.
In terms of IVIG market size by volume, the US accounted for the
maximum share with ……..tonnes of IVIG, followed by the EU with
……….tonnes of contribution in the global IVIG market as of 2011. In
terms of value, the U.S. market was worth ……..billion approximately
in 2011.
 The IVIG market in the US stood at US$............billion in 2011,
recording an increase of nearly ……..% over US$......... billion worth
sales generated in 2010. The CAGR recorded over the cited period
was ……..%.
Sales of IVIG in the US (2001-2011)IVIG Market Volume by Region (2005, 2008 and 2011)
)
Global IVIG Demand and Supply (2007-2012E)
2005 2008 2011
Tonnes
USA EU RoW
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
US$Billion
2007 2008 2009 2010 2011 2012E
Tonnes
Demand Supply

5. Immunoglobulin market is highly competitive represented by key players including Grifols, Baxter, and
CSL.
On the contention front, the comparatively low price of CSL’s IVIGs, both its
liquid, Privigen, and low cost lyophilised IVIG, position the company as a
dominant supplier of the same. On the other hand, Baxter’s Gammaguard
has depicted a wavy pattern in terms of pricing over the mentioned period,
reaching its highest US$........gram in June 2012.
Within Europe, the IVIG market was dominated by Grifols, CSL, and Baxter
with respective shares of ……….%, …..% and …….% as of 2011. Kedrion
was another major player constituting ………..% of the same
Of the overall North American IVID market, Grifols and Baxter collectively
accounted for ………% share, while CSL accounted for ………..% of the
same as of the year end 2011.
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
Jun-09 Jun-10 Jun-11 Jun-12 Jun-13
US$/g
Privigen (CSL) Gammunex (Grifols)
Gammaguard (Baxter)
Grifols CSL Baxter Kedrion
Octapharma Biotest Others
Pricing of Leading IVIG Products (June 2009-June 2013)
Europe’s IVIG Market Share (2011)
Grifols Baxter CSL
Kedrion Octapharma Others
North America’s IVIG Market Share (2011)

6. Table of Contents
1. Overview
1.1 Components of Blood Plasma
1.2 Collection and Extraction of Plasma
1.2.1 Plasma Collection
1.2.2 Plasma Extraction
1.2.3 Plasma Fractionation Yield
1.3 Immunoglobulins: Intravenous immunoglobulin (IVIG)
1.3.1 IVIG’s Action Mechanism
1.3.2 IVIG Dosage and Administration
2. Market Size
2.1 Global Blood Plasma Market
-Market Value
-Market Segmentation
2.2 Global IVIG Market
-Market Value
-Demand & Supply
-Regional Breakdown
2.2.1 IVIG Market of the US
-Market Value
-Price Trend
3. Market Dynamics
3.1 Industry Trends and Developments
3.1.1 Reimbursement
3.2 Growth Drivers
3.2.1 Rising Healthcare Expenditure
3.2.2 Higher Spending on Medicines
3.2.3 Rising Demand for Better Healthcare Options
3.2.4 Launch of NMEs (New Molecular Entities)
List of Charts & Tables
List of Charts
Plasma Extraction from Donated Blood (Recovered Plasma)
Plasmapheresis (Source Plasma)
Global Blood Plasma Market (2000-2011)
Global Plasma Market Share by Product (2011)
Global IVIG Market Size (2004-2011)
Global IVIG Demand and Supply (2007-2012E)
IVIG Market Volume by Region (2005, 2008 and 2011)
Global IVIG Market Share by Geography (2011)
IVIG Use by Indication
Sales of IVIG in the US (2001-2011)
Lyophilised and Liquid IVIG Average Pricing in the US (March 2007-March
2013)
Global Healthcare Spending (2005-2015E)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Biotechnology Therapeutics Under Development (2011)
Global Plasma Market Share by Company (2011)
Pricing of Leading IVIG Products (June 2009-June 2013)
Capacity Expansion Plans of the Key Industry Players (2012 and 2016E)
Europe’s IVIG Market Share (2011)
North America’s IVIG Market Share (2011)
The US IVIG Market (2011)
The US IG Sales Share by Value (2012)
Baxter’s Revenue by Business Segments (2012)
Baxter’s Revenues and Net Income (2008-2012)
Grifols Revenue Share by Business Segments (2012)
Grifols’ Revenues & Net Profit (2008-2012)
CSL’s Revenue Share by Major Products (2011-12)
CSL’s Revenues and Net Profit (2008/09-2011/12)
Global Blood Plasma Market Forecast (2009-2015F)

7. 3.3 Challenges
3.3.1 Increasing Regulation in Plasma-collection Industry
3.3.2 Mounting Price Pressure
3.3.3 Constrained Plasma Fractionation Capacity
3.3.4 Misdiagnosis of the Disease
4. Competitive Landscape
4.1 Immunoglobulins’ Market Contention
4.1.1 IVIG Market of Europe
4.1.2 IVIG Market of North America
4.1.3 IVIG Market of the US
5. Company Profiles
5.1 Baxter International Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Advancing the Core Portfolio Globally
-Expansion of Product Portfolio
5.2 Grifols
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Expansion in Other Regions
-Growth through Acquisitions
5.3 CSL Limited
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Focus on R&D
-Expanding Product Portfolio
List of Tables
Constituents of Blood Plasma
Recovered plasma vs. Source plasma
Output per Liter of Plasma
Breakdown of US IVIG usage by patient share (%) and volume share
(%) by indication
Breakdown of US SCIG and IVIG usage by volume share (FY11)
US Centre for Medicare and Medicaid (CMS) Reimbursement
Patients Worldwide Waiting for Better Treatment Options (2011)
Global Availability of NMEs (2011)
IVIG Product Characteristics
Dependent & Independent Variables (2007-2011)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

8. 6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

9. Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T. +91-120-4130959
C: +91-9811715635
vikas@konceptanalytics.com
Contact Us:
www.konceptanalytics.com
Vikas Gupta
BD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “Global IVIG Market”. To know more
about this report or for any customized research requirement, please contact the following:
View Report Details